You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 10,071,139

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,071,139

Title:	Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment
Abstract:	Methods and compositions for reducing one or more of triglyceride levels, total cholesterol levels and LDL cholesterol levels in a subject are provided. The methods include administering a fragment of ANGPTL8 to a subject having or at risk of developing elevated triglyceride levels, elevated total cholesterol levels and/or elevated LDL cholesterol levels.
Inventor(s):	Liu; Zhonghao (San Bruno, CA), Ding; Xunshan (San Bruno, CA)
Assignee:	NGM Biopharmaceuticals, Inc. (South San Francisco, CA)
Application Number:	15/318,937
Patent Claims:	1. A method of reducing triglyceride levels in a subject having or at risk of developing elevated triglyceride levels, the method comprising: administering to the subject a polypeptide comprising a contiguous amino acid sequence having at least 95% sequence identity to the amino acid sequence of amino acids 80-198 of full-length angiopoietin-like protein 8 (ANGPTL8) (SEQ ID NO. 1), wherein the polypeptide lacks the amino acids 21-70 of full-length ANGPTL8 (SEQ ID NO: 1), and wherein the polypeptide is administered in an amount effective to reduce the triglyceride levels in the subject. 2. The method of claim 1, wherein the contiguous amino acid sequence has at least 97% sequence identity to the amino acid sequence of amino acids 80-198 of full-length ANGPTL8 (SEQ ID NO. 1). 3. The method of claim 1, wherein the contiguous amino acid sequence has at least 99% sequence identity to the amino acid sequence of amino acids 80-198 of full-length ANGPTL8 (SEQ ID NO. 1). 4. The method of claim 1, wherein the contiguous amino acid sequence has the amino acid sequence of amino acids 80-198 of full-length ANGPTL8 (SEQ ID NO. 1). 5. The method of claim 4, wherein the subject has elevated triglyceride levels. 6. The method of claim 5, wherein the subject is overweight or obese. 7. The method of claim 1, wherein a heterologous polypeptide is conjugated to the N-terminus or C-terminus of the polypeptide. 8. The method of claim 7, wherein the heterologous polypeptide is albumin or human serum albumin. 9. The method of claim 7, wherein the heterologous polypeptide is conjugated to the polypeptide via a cleavable linker sequence or a non-cleavable linker sequence. 10. The method of claim 7, wherein the heterologous polypeptide is an immunoglobulin Fc. 11. The method of claim 1, wherein the administering reduces triglyceride levels by at least 5% compared to triglyceride levels in the subject prior to the administering of the polypeptide. 12. The method of claim 1, wherein the administering reduces triglyceride levels by at least 10% compared to triglyceride levels in the subject prior to the administering of the polypeptide. 13. The method of claim 1, wherein the administering reduces triglyceride levels by at least 20% compared to triglyceride levels in the subject prior to the administering of the polypeptide. 14. The method of claim 1, wherein the subject is overweight or obese. 15. The method of claim 1, wherein the subject has diabetes. 16. The method of claim 1, wherein the subject has hypothyroidism. 17. The method of claim 1, wherein the subject has elevated triglyceride levels. 18. The method of claim 17, wherein an immunoglobulin Fc is conjugated to the N-terminus or C-terminus of the polypeptide. 19. The method of claim 5, wherein an immunoglobulin Fc is conjugated to the N-terminus or C-terminus of the polypeptide. 20. The method of claim 6, wherein an immunoglobulin Fc is conjugated to the N-terminus or C-terminus of the polypeptide.

Details for Patent 10,071,139

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	2034-10-03
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	2034-10-03
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	2034-10-03
Grifols Biologicals Llc	ALBUTEIN	albumin (human)	Injection	102478	08/15/1978	⤷ Try a Trial	2034-10-03
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	02/17/1995	⤷ Try a Trial	2034-10-03
Instituto Grifols, S.a.	HUMAN ALBUMIN GRIFOLS	albumin (human)	Injection	103352	06/11/2003	⤷ Try a Trial	2034-10-03
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.